Warner-lambert Company

David W Moreland

Haile Tecle

Walter H Moos

David A Downs

Thomas Gary Heffner

Stephen C Bergmeier

Leonard Theodore Meltzer

Linda L Coughenour

Robert E Davis

Certain N-substituted 1-(1,2,3,6-tetrahydro-3-pyridinyl)oximes and N-substituted 1-(1,2,3,6-tetrahydro-4-pyridinyl)oximes are useful as sigma binding agents for the treatment of depression, psychoses and/or inflammatory diseases.

Methods of treating depression and psychoses

Tetrahydropyridine oxime compounds

Certain N-substituted 1-(1,2,3,6-tetrahydro-3-pyridinyl)oximes and N-substituted 1-(1,2,3,6-tetrahydro-4-pyridinyl)oximes are useful as analgesic agents or agents for the teatment or amelioration of the symptoms of cerebral insufficiency characterized by decreased central acetylcholine production or release.

Tetrahydropyridine oxime cholinergic agents and method of treatment

Certain O-substituted-1,2,5,6-tetrahydro-3- or 1,2,3,6-tetrahydro-4-pyridine oximes are useful as agents for treating pain or for treating the symptoms of senile cognitive decline.

O-substituted tetrahydropyridine oxime cholinergic agents

Certain O-substituted 1-(1,2,3,6-tetrahydro-1-methyl-3-pyridinyl)ketone oximes and O-substituted 1-(1,2,3,6-tetrahydro-4-pyridinyl)ketone oximes are useful as analgesic agents or agents for the treatment or amelioration of the symptoms of cerebral insufficiency characterized by decreased central acetylcholine production or release. Pharmaceutical compositions containing the compounds and methods of using the compositions in a pharmaceutical method are also disclosed.

Growing community of inventors

Ann Arbor, MI, United States of America

David W Moreland